Skip to main content

Edwards Lifesciences Corp income statement

  • EW · NYSE
  • Medical devices
  • Health Care Equipment
  • S&P 500
$107.15+1.28%Close 13 Nov 2026 · Market value $61.47B

Edwards Lifesciences Corp reported revenue of $6.07 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), up 11.5% from fiscal 2024. Net income was $1.07 billion and diluted earnings per share $1.83.

From Edwards Lifesciences Corp's annual and quarterly reports, each period checked against accounting identities; a figure that does not pass is left blank. Fiscal years follow the company's calendar, the latest ending 31 Dec 2025. TTM is the last four reported quarters added up.

Annual

Edwards Lifesciences Corp income statement, annual
USDFY 2008FY 2009FY 2010FY 2011FY 2012FY 2013FY 2014FY 2015FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Revenue$1.24B$1.32B$1.45B$1.68B$1.90B$2.05B$2.32B$2.49B$2.96B$3.44B$3.72B$4.35B$4.39B$5.23B$4.46B$5.01B$5.44B$6.07B$6.67B
Revenue growth—+6.8%+9.5%+16.0%+13.2%+7.7%+13.6%+7.4%+18.8%+15.9%+8.4%+16.8%+0.9%+19.3%−14.7%+12.2%+8.6%+11.5%—
Net interest income———$300.0K$400.0K−$5.20M−$10.80M———−$29.90M————−$17.60M−$19.80M−$20.40M−$32.90M
Cost of revenue$419.6M$399.1M$408.3M$489.8M$491.0M$516.6M$625.6M$617.2M$797.4M$875.3M$939.4M$1.11B$1.08B$1.25B$723.7M$978.4M$1.12B$1.33B$1.47B
Gross profit$818.1M$922.3M$1.04B$1.19B$1.41B$1.53B$1.70B$1.88B$2.17B$2.56B$2.78B$3.23B$3.31B$3.98B$3.74B$4.03B$4.32B$4.73B$5.21B
Gross margin66.1%69.8%71.8%70.8%74.2%74.7%73.1%75.2%73.1%74.5%74.8%74.4%75.4%76.1%83.8%80.5%79.5%78.0%78.0%
Research and development$139.2M$175.5M$204.4M$246.3M$291.3M$323.0M$346.5M$382.9M$442.2M$552.6M$622.2M$752.7M$760.7M$903.1M$843.6M$962.9M$1.05B$1.08B$1.09B
Selling, general and administrative$480.6M$508.8M$550.0M$642.4M$697.4M$733.4M$858.0M$850.7M$904.7M$990.8M$1.09B$1.24B$1.23B$1.49B$1.36B$1.58B$1.79B$2.09B$2.25B
Operating expenses——$768.1M$902.1M———$1.24B——————$2.24B————
Operating income$171.6M$300.7M$270.6M$283.3M$387.8M$516.4M$1.15B$639.6M$751.2M$1.09B$748.2M$1.15B$897.6M$1.69B$1.50B$1.31B$1.38B$1.26B$1.44B
Operating margin13.9%22.8%18.7%16.9%20.4%25.2%49.7%25.6%25.3%31.7%20.1%26.4%20.5%32.3%33.6%26.1%25.3%20.8%21.6%
Interest expense$7.20M$2.70M$2.40M$3.10M$4.40M$9.80M$17.20M$17.20M$19.20M$23.20M$29.90M$20.70M$15.80M$18.40M$19.20M$17.60M$19.80M$20.40M—
Other income and expense−$7.70M$3.70M$8.10M$4.80M——————————$21.10M$63.50M$169.4M$8.70M−$8.60M
Income before tax$164.4M$304.4M$268.2M$283.6M$388.2M$511.2M$1.14B$622.4M$737.9M$1.03B$761.4M$1.17B$916.7M$1.70B$1.52B$1.37B$1.55B$1.27B$1.43B
Income tax expense$35.50M$75.30M$50.20M$46.90M$96.70M$122.1M$332.9M$127.5M$168.4M$451.3M$39.20M$119.6M$93.30M$198.9M$195.5M$152.4M$152.1M$216.9M$444.7M
Effective tax rate21.6%24.7%18.7%16.5%24.9%23.9%29.1%20.5%22.8%43.6%5.1%10.3%10.2%11.7%12.9%11.1%9.8%17.0%31.0%
Net income$128.9M$229.1M$218.0M$236.7M$291.5M$389.1M$811.1M$494.9M$569.5M$583.6M$722.2M$1.05B$823.4M$1.50B$1.52B$1.40B$4.17B$1.07B$1.02B
Net margin10.4%17.3%15.1%14.1%15.3%19.0%34.9%19.8%19.2%17.0%19.4%24.1%18.8%28.7%34.1%28.0%76.7%17.7%15.3%
Net income to common shareholders$130.6M$229.1M$218.0M$236.7M$291.5M$389.1M$811.1M$494.9M$569.5M$583.6M$722.2M$1.05B$823.4M$1.50B$1.52B$1.40B———
EPS · diluted$0.18$0.32$0.30$0.33$0.41$0.57$1.25$0.75$0.87$0.90$1.13$1.64$1.30$2.38$2.44$2.30$6.97$1.83$1.76
Diluted weighted average shares715M705M715M716M710M683M651M661M653M648M641M637M632M631M624M609M599M586M579M
Basic weighted average shares670M675M682M688M689M670M639M647M639M633M628M625M623M623M619M607M598M585M578M
EBITDA$227.2M$359.4M$327.1M$341.3M$441.5M$579.3M$1.22B$705.4M$822.4M$1.17B$825.6M$1.24B$1.00B$1.83B$1.64B$1.45B$1.53B$1.42B$1.61B
EBITDA margin18.4%27.2%22.6%20.3%23.2%28.3%52.7%28.3%27.7%34.1%22.2%28.4%22.9%34.9%36.7%29.0%28.2%23.4%24.2%
Depreciation & amortization$55.60M$58.70M$56.50M$58.00M$53.70M$62.90M$68.60M$65.80M$71.20M$81.90M$77.40M$89.30M$107.2M$134.8M$139.6M$144.9M$155.2M$156.6M$171.2M
Stock-based compensation$28.70M$28.30M$29.30M$35.00M$42.10M$47.40M$48.30M$49.90M$56.90M$61.60M$71.00M$81.30M$92.60M$109.3M$126.8M$139.4M$162.3M$158.1M$172.8M

Quarterly

Edwards Lifesciences Corp income statement, quarterly
USDQ4 FY2023Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Revenue$1.27B$1.33B$1.37B$1.35B$1.39B$1.41B$1.53B$1.55B$1.57B$1.65B$1.74B$1.72B
Net interest income−$50.40M$16.50M$15.50M$24.30M−$76.10M$36.50M$37.40M$38.60M−$132.9M$33.50M$30.00M$36.50M
Cost of revenue$251.0M$286.9M$275.5M$262.9M$292.2M$301.6M$344.4M$345.2M$343.0M$362.6M$392.4M$369.2M
Gross profit$1.02B$1.04B$1.09B$1.09B$1.09B$1.11B$1.19B$1.21B$1.23B$1.29B$1.35B$1.35B
Gross margin80.2%78.4%79.9%80.6%78.9%78.7%77.5%77.8%78.1%78.0%77.5%78.5%
Research and development$351.0M$256.7M$271.8M$253.4M$271.1M$254.6M$276.2M$280.7M$267.7M$263.3M$278.9M$281.4M
Selling, general and administrative$658.7M$428.4M$447.5M$421.4M$491.9M$465.7M$502.0M$514.6M$602.9M$522.2M$561.2M$560.9M
Operating expenses—$694.0M$727.4M——$716.3M$776.6M———$835.4M—
Operating income$572.0M$349.0M$366.5M$350.6M$312.6M$394.8M$411.2M$307.1M$151.1M$477.6M$513.2M$299.1M
Operating margin45.2%26.2%26.8%25.9%22.6%27.9%26.8%19.8%9.6%29.0%29.5%17.4%
Other income and expense—$22.20M$17.50M$52.20M$77.50M$39.10M−$11.00M$41.30M−$60.70M−$18.60M$6.60M$64.10M
Income before tax$592.9M$371.2M$384.0M$402.8M$390.1M$433.9M$400.2M$348.4M$90.40M$459.0M$519.8M$363.2M
Income tax expense$80.40M$46.30M$20.00M$40.70M$45.10M$70.30M$64.30M$56.10M$26.20M$78.30M$278.4M$61.80M
Effective tax rate13.6%12.5%5.2%10.1%11.6%16.2%16.1%16.1%29.0%17.1%53.6%17.0%
Net income$369.9M$351.9M$366.3M$3.07B$385.6M$358.0M$333.2M$291.1M$91.20M$380.7M$241.9M$307.5M
Net margin29.2%26.5%26.7%227%27.8%25.3%21.7%18.7%5.8%23.1%13.9%17.9%
Net income to common shareholders$369.9M$351.9M——————————
EPS · diluted$0.61$0.58$0.61$5.13$0.65$0.61$0.56$0.50$0.16$0.66$0.42$0.53
Diluted weighted average shares607M604M604M598M591M588M588M586M582M581M578M578M
Basic weighted average shares605M602M602M597M590M587M587M585M581M579M576M576M
EBITDA$608.7M$387.5M$406.1M$385.1M$355.2M$431.4M$449.3M$346.3M$193.8M$518.5M$555.9M$344.0M
EBITDA margin48.1%29.1%29.7%28.4%25.6%30.5%29.3%22.3%12.3%31.5%31.9%20.1%
Depreciation & amortization$36.70M$38.50M$39.60M$34.50M$42.60M$36.60M$38.10M$39.20M$42.70M$40.90M$42.70M$44.90M
Stock-based compensation$30.50M$44.60M$43.90M$42.10M$31.70M$40.20M$37.50M$41.20M$39.20M$45.40M$42.20M$46.00M

The main figures as JSON and plain text. See data and methodology.

EW in the terminal

Every line back twenty years, charts of any figure, segments and KPIs by quarter, valuation and alerts.